Tivic Health® Systems, Inc. has secured an exclusive Techwatch meeting with BARDA's Radiological and Nuclear Medical Countermeasures Program.
The meeting will focus on presenting clinical data on Entolimod's effects on acute radiation syndrome and manufacturing readiness for a biologics license application.
Entolimod, Tivic's lead drug candidate, has shown promise in trials and has been granted Fast Track and Orphan Drug designations by the FDA.
BARDA Meeting
Tivic secured an exclusive Techwatch meeting with BARDA, showcasing Entolimod's potential.
Entolimod's Efficacy
Clinical studies indicate Entolimod's effectiveness in treating acute radiation syndrome.
Regulatory Designations
Entolimod has been granted Fast Track and Orphan Drug designations by the FDA.
- The meeting aims to establish development pathways for Entolimod, potentially leading to deployment in mass-casualty situations.
- Tivic's strategy of developing therapeutic assets with potential government partnerships aligns with the federal demand for radiation injury treatments.
Tivic's engagement with BARDA signifies progress in the development of Entolimod for treating acute radiation syndrome, paving the way for potential government collaborations and regulatory approvals.